LLY vs MYNZ

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

MYNZ presents an exceptionally high-risk, ultra-speculative scenario, even more so than previously assessed. The company has undergone a complete pivot, discontinuing its colorectal cancer screening business (ColoAlert IP is being sold) and shifting entirely to post-quantum cybersecurity (Quantum Cyber brand). This pivot is accompanied by a severe recapitalization event where existing shareholders...